It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Memory formation is key for brain functioning. Uncovering the memory mechanisms is helping us to better understand neural processes in health and disease. Moreover, more specific treatments for fear-related disorders such as posttraumatic stress disorder and phobias may help to decrease their negative impact on mental health. In this line, the Tachykinin 2 (Tac2) pathway in the central amygdala (CeA) has been shown to be sufficient and necessary for the modulation of fear memory consolidation. CeA-Tac2 antagonism and its pharmacogenetic temporal inhibition impair fear memory in male mice. Surprisingly, we demonstrate here the opposite effect of Tac2 blockade on enhancing fear memory consolidation in females. Furthermore, we show that CeA-testosterone in males, CeA-estradiol in females and Akt/GSK3β/β-Catenin signaling both mediate the opposite-sex differential Tac2 pathway regulation of fear memory.
The Tachykinin 2 (Tac2) pathway in the central amygdala is sufficient and necessary for modulating fear memory consolidation. The authors show that silencing Tac2 neurons in the amygdala of male mice reduces fear expression, while fear expression in female mice is increased when manipulations are made during proestrus.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 Universitat Autònoma de Barcelona, Institut de Neurociències, Cerdanyola del Vallès, Barcelona, Spain (GRID:grid.7080.f) (ISNI:0000 0001 2296 0625); Universitat Autònoma de Barcelona, Departament de Psicobiologia i de Metodologia de les Ciències de la Salut, Cerdanyola del Vallès, Barcelona, Spain (GRID:grid.7080.f) (ISNI:0000 0001 2296 0625)
2 Universitat Autònoma de Barcelona, Institut de Neurociències, Cerdanyola del Vallès, Barcelona, Spain (GRID:grid.7080.f) (ISNI:0000 0001 2296 0625)
3 Universitat Autònoma de Barcelona, Institut de Neurociències, Cerdanyola del Vallès, Barcelona, Spain (GRID:grid.7080.f) (ISNI:0000 0001 2296 0625); Universitat Autònoma de Barcelona, Department de Bioquímica i Biologia Molecular, Facultat de Medicina, Cerdanyola del Vallès, Barcelona, Spain (GRID:grid.7080.f) (ISNI:0000 0001 2296 0625); Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain (GRID:grid.418264.d) (ISNI:0000 0004 1762 4012)
4 Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain (GRID:grid.411142.3) (ISNI:0000 0004 1767 8811)
5 Universitat Autònoma de Barcelona, Institut de Neurociències, Cerdanyola del Vallès, Barcelona, Spain (GRID:grid.7080.f) (ISNI:0000 0001 2296 0625); Universitat Autònoma de Barcelona, Unitat de Fisiologia Animal, Departament de Biologia Cel·lular, Fisiologia i Immunologia. Facultat de Biociències, Cerdanyola del Vallès, Barcelona, Spain (GRID:grid.7080.f) (ISNI:0000 0001 2296 0625)
6 Universitat Autònoma de Barcelona, Institut de Neurociències, Cerdanyola del Vallès, Barcelona, Spain (GRID:grid.7080.f) (ISNI:0000 0001 2296 0625); Universitat Autònoma de Barcelona, Departament de Psicobiologia i de Metodologia de les Ciències de la Salut, Cerdanyola del Vallès, Barcelona, Spain (GRID:grid.7080.f) (ISNI:0000 0001 2296 0625); Centro de Investigación Biomédica En Red en Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain (GRID:grid.469673.9) (ISNI:0000 0004 5901 7501); Universitat Autònoma de Barcelona, Unitat de Neurociència Traslacional, Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació Parc Taulí (I3PT), Cerdanyola del Vallès, Barcelona, Spain (GRID:grid.7080.f) (ISNI:0000 0001 2296 0625)
7 Universitat Autònoma de Barcelona, Institut de Neurociències, Cerdanyola del Vallès, Barcelona, Spain (GRID:grid.7080.f) (ISNI:0000 0001 2296 0625); Universitat Autònoma de Barcelona, Departament de Psicobiologia i de Metodologia de les Ciències de la Salut, Cerdanyola del Vallès, Barcelona, Spain (GRID:grid.7080.f) (ISNI:0000 0001 2296 0625); Centro de Investigación Biomédica En Red en Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain (GRID:grid.469673.9) (ISNI:0000 0004 5901 7501); Universitat Autònoma de Barcelona, Unitat de Neurociència Traslacional, Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació Parc Taulí (I3PT), Cerdanyola del Vallès, Barcelona, Spain (GRID:grid.7080.f) (ISNI:0000 0001 2296 0625); ICREA, Barcelona, Spain (GRID:grid.425902.8) (ISNI:0000 0000 9601 989X)